ArticleJournal of nanobiotechnology2026
Circulating miR-378a-3p attenuates pulmonary inflammation and fibrosis via BAT-lung crosstalk.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Pulmonary fibrosis (PF) arises from persistent fibroblast activation and inflammation. Although microRNAs (miRNAs) are promising antifibrotic agents, the contribution of adipose-derived circulating miRNAs to PF remains unclear. Here, we identify brown adipose tissue (BAT) as a major source of exosomal miR-378a-3p that counteracts bleomycin (BLM)-induced PF. In fibrotic mice, BAT activity and circulating exosomal miR-378a-3p were reduced. Activating BAT by cold exposure or β3-adrenergic stimulation increased circulating and pulmonary miR-378a-3p and attenuated collagen deposition and inflammatory infiltration. Adipocyte-specific deletion of miR-378a-3p exacerbated lung inflammation and fibrosis, whereas lung-targeted overexpression of miR-378a-3p or intravenous delivery of BAT-derived exosomes enriched for miR-378a-3p ameliorated disease. Inhibition of exosome release from BAT lowered circulating miR-378a-3p and blunted the anti-fibrotic benefits of BAT activation, supporting a BAT-to-lung transfer mechanism. Mechanistically, miR-378a-3p targets Itga5 to suppress FAK-PI3K-AKT signaling and limiting fibroblast activation, while simultaneously suppressing macrophage inflammatory responses by targeting Fstl1 and suppressing NF-κB activation. Collectively, these findings identify miR-378a-3p as a BAT-derived signaling molecule with dual anti-inflammatory and anti-fibrotic effects in pulmonary fibrosis, expanding the pathophysiological scope of BAT-mediated inter-organ communication to lung disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.